BRPI0410315A - 2-imidazo-benzotiazóis como ligandos de receptor de adenosina - Google Patents

2-imidazo-benzotiazóis como ligandos de receptor de adenosina

Info

Publication number
BRPI0410315A
BRPI0410315A BRPI0410315-7A BRPI0410315A BRPI0410315A BR PI0410315 A BRPI0410315 A BR PI0410315A BR PI0410315 A BRPI0410315 A BR PI0410315A BR PI0410315 A BRPI0410315 A BR PI0410315A
Authority
BR
Brazil
Prior art keywords
sup
benzothiazoles
imidazo
sub
receptor ligands
Prior art date
Application number
BRPI0410315-7A
Other languages
English (en)
Inventor
Alexander Flohr
Roland Jakob-Roetne
Roger David Norcross
Claus Riemer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0410315A publication Critical patent/BRPI0410315A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)

Abstract

"2-IMIDAZO-BENZOTIAZóIS COMO LIGANDOS DE RECEPTOR DE ADENOSINA". A invenção refere-se aos 2-imidazo-benzotiazóis da fórmula geral I, em que R¬ 1¬ é fenila ou um heterociclo contendo N e/ou O; R¬ 2¬ é um imidazol ou um imidazol anulado, selecionado do grupo que consiste em, a), b), c), d) ou e), R¬ 3¬ é hidrogênio, fenila, 2,3-dihidro-benzo-¢1,4!dioxin-6-ila, benzo¢b!tiofen-3-ila, 3-metil-benzo¢b!tiofen-2-ila, tiofen-2-ila, tiofen-3-ila ou tiofen2-il-metila, R¬ 4¬ é hidrogênio, -(CH~ 2~)~ n~O-alquila inferior ou alquila inferior; R¬ 5¬ é hidrogênio, alquila inferior, halogênio, morfolinila, -NR<39>R<39><39>, piperidinila, opcionalmente substituído por hidróxi, ou é pirrolidin-1-ila; R¬ 6¬ é hidrogênio, benzila ou -(CH~ 2~)~ n~O-alquila inferior, R¬ 7¬ é hidrogênio, -C(O)O-alquila inferior, -C(O)C~ 6~H~ 4~-halogênio, -C(O)-C~ 6~H~ 4~-alquila inferior, -C(O)-alquila inferior, -C(O)cicloalquila, -C(O)-NR<39>R<39><39>, -C(O)-(CH~ 2~)~ n~O-alquila inferior, -S(O)~ 2~-alquila inferior, -(CH~ 2~)~ n~O-alquila inferior, -C(O)-piridin-4-ila cujo anel pode ser substituído por alquila inferior, halogênio-alquila inferior ou por pirrol-1-il-metila, ou é (CH~ 2~)~ n~-C(O)-NR<39>R<39><39>; R<39>/R<39><39> são independentemente um do outro hidrogênio, alquila inferior ou -(CH~ 2~)~ n~-tetrahidropiran-4-ila, X é -CH~ 2~-, -NR<39><39><39>- ou -O-; R<39><39><39> é hidrogênio, -C(O)-alquila inferior, -C(O)O-alquila inferior, -C(O)-C~ 6~H~ 4~CH~ 3~ ou benzila; n é 1 ou 2; e aos sais de adição de ácido farmaceuticamente aceitáveis destes. Estes compostos são ligandos de receptor de adenosina e portanto adequados para o tratamento de doenças relacionadas a este receptor.
BRPI0410315-7A 2003-05-13 2004-05-06 2-imidazo-benzotiazóis como ligandos de receptor de adenosina BRPI0410315A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03009842 2003-05-13
PCT/EP2004/004843 WO2004101558A1 (en) 2003-05-13 2004-05-06 2-imidazo-benzothiazoles as adenosine receptor ligands

Publications (1)

Publication Number Publication Date
BRPI0410315A true BRPI0410315A (pt) 2006-05-23

Family

ID=33395778

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410315-7A BRPI0410315A (pt) 2003-05-13 2004-05-06 2-imidazo-benzotiazóis como ligandos de receptor de adenosina

Country Status (15)

Country Link
US (1) US7122545B2 (pt)
EP (1) EP1636217B1 (pt)
JP (1) JP4408291B2 (pt)
KR (1) KR100710453B1 (pt)
CN (1) CN100372844C (pt)
AT (1) ATE407133T1 (pt)
AU (1) AU2004238508B2 (pt)
BR (1) BRPI0410315A (pt)
CA (1) CA2523959A1 (pt)
DE (1) DE602004016328D1 (pt)
ES (1) ES2313001T3 (pt)
MX (1) MXPA05012120A (pt)
PL (1) PL1636217T3 (pt)
RU (1) RU2340612C2 (pt)
WO (1) WO2004101558A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345178B2 (en) * 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
SG174125A1 (en) * 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
CA2756989A1 (en) * 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
US10155777B2 (en) 2015-04-08 2018-12-18 University Of Delaware Trans-cycloheptenes and hetero-trans-cycloheptenes for bioorthogonal coupling
WO2018193090A2 (en) * 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
KR20200043433A (ko) 2017-08-21 2020-04-27 메르크 파텐트 게엠베하 아데노신 수용체 길항제로서의 벤즈이미다졸 유도체
WO2025160629A1 (en) * 2024-01-31 2025-08-07 Certa Therapeutics Pty Ltd Proton sensing gpcr modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI91859C (fi) * 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
US6037473A (en) * 1997-11-13 2000-03-14 Haarmann & Reimer Gmbh Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation
WO2001002400A1 (en) * 1999-07-02 2001-01-11 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
RU2251419C2 (ru) * 2000-06-21 2005-05-10 Ф. Хоффманн-Ля Рош Аг Производные бензотиазола
EP1628662B1 (en) * 2003-05-21 2007-02-14 F. Hoffmann-La Roche Ag Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor

Also Published As

Publication number Publication date
CA2523959A1 (en) 2004-11-25
DE602004016328D1 (de) 2008-10-16
JP2006528215A (ja) 2006-12-14
KR20060009928A (ko) 2006-02-01
RU2005138546A (ru) 2006-07-27
AU2004238508B2 (en) 2009-11-19
KR100710453B1 (ko) 2007-04-24
CN1780831A (zh) 2006-05-31
EP1636217B1 (en) 2008-09-03
US7122545B2 (en) 2006-10-17
AU2004238508A1 (en) 2004-11-25
JP4408291B2 (ja) 2010-02-03
ATE407133T1 (de) 2008-09-15
EP1636217A1 (en) 2006-03-22
RU2340612C2 (ru) 2008-12-10
US20040229862A1 (en) 2004-11-18
PL1636217T3 (pl) 2009-02-27
MXPA05012120A (es) 2006-02-08
ES2313001T3 (es) 2009-03-01
WO2004101558A1 (en) 2004-11-25
CN100372844C (zh) 2008-03-05

Similar Documents

Publication Publication Date Title
TW200505902A (en) Cannabinoid receptor ligands
FR2838439B1 (fr) Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
WO2006050161A3 (en) Therapeutic furopyrimidines and thienopyrimidines
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
EA200300595A1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
IL161074A0 (en) Lactam derivatives as antagonists for human 11cby receptors
ATE406360T1 (de) Antagonisten der opioidrezeptoren
NZ541974A (en) Nucleotide phosphoramidates as anticancer agents
MX2008000141A (es) Moduladores de lxr basados en imidazol.
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
EA200401455A1 (ru) Производные бензоксазина в качестве модуляторов 5-htи их применение
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
DK1643984T3 (da) Anvendelse af parthenolidderivater som antileukæmiske og cytotoksske midler
ATE308522T1 (de) Opioidrezeptorantagonisten
BR0313385A (pt) Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
ATE407133T1 (de) 2-imidazo-benzothiazole als adenosin-rezeptor liganden
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
ATE516291T1 (de) Thenopyrimidin-verbindungen mit fungizider aktivität
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren
WO2006041631A3 (en) Novel cyclosporin alkynes and their utility as pharmaceutical agents

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.